Delivra Announces Record Sales Growth for the Quarter

TORONTO, ON--(Marketwired - November 22, 2017) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") reported its financial results for the three and nine months ended September 30, 2017. All figures are reported in CDN dollars ($), unless otherwise indicated. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Q3 2017 Financial and Operational Highlights:

• OTC sales of $923,850 for the quarter and $3,297,836 for the year-to-date, representing a 47% and 21% growth over the comparative periods, respectively;
• Significant operating efficiencies in the quarter and year-to-date over the comparative periods, through the optimization of expenses, resulting in a 57% and 37% reduction in operating expenditures, respectively, while continue to grow OTC sales; and
• Continued to reduce cash flow expenditures in operating activities over the past four quarters, while delivering 21% growth in OTC sales in the year-to-date.

"Building on the momentum of the first half of the year, the Company continues to show quarter-after-quarter reduction in cash used in operating activities, as a result of, increased sales of our flagship pain and nerve products with a disciplined focus on cost efficiencies. With increased revenue and strong margins, Delivra has built a platform to develop and commercialize therapeutics to deliver value-added treatments that meet unique and important healthcare needs and provide additional opportunities to drive revenue for the Company," said Joseph Gabriele, Chief Executive Officer of Delivra.

Selected Financial Summary
CDN$ 000s (except		For the three months		For the three months		For the nine months		For the nine months
earnings per share and		ended September 30,		ended September 30,		ended September 30,		ended September 30,
percentages		2017		2016		2017		2016
Revenue		924		630		3,298		2,735
Gross profit		658		407		2,336		1,864
Gross profit margin		71%		65%		71%		68%
Net loss per share - basic		0.01		0.06		0.03		0.11

Delivra's unaudited condensed interim consolidated financial statements and management's discussion & analysis ("MD&A"), for the three and nine months ended September 30, 2017, are available via Delivra's website at www.delivracorp.com and will be available on SEDAR at www.sedar.com.